1. Home
  2. Mandates
  3. Vinge advises Oncopeptides in connection with a directed share issue

Mandate Vinge advises Oncopeptides in connection with a directed share issue

June 28, 2019

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 727 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Carnegie Investment Bank AB (publ), Cowen, DNB Markets, a part of DNB Bank ASA, Jefferies International Limited and Kempen & CO N.V.

Oncopeptides is a clinical development pharmaceutical company focused on conducting anti-cancer research to develop treatments for the benefit of patients. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Sofie Bjärtun and Hampus Olsson.

Summary of employment related news in Sweden as of January 2021

 Short-time work, a new pandemic law and pending changes to the Employment Protection Act. Here is the latest employment related news in Sweden.
January 19, 2021

Vinge in first place when the transaction year 2020 is summarized
January 07, 2021

Sanctions round-up

Not so long ago, sanctions were a rare occurrence which only involved obscure products and countries, and which were decided by the members of the United Nations Security Council. Today, the European Union and particularly the United States, impose sanctions and other trade restrictions with high frequency which have the potential to affect any type of transaction. Set forth below is a summary of some recent developments.
December 22, 2020